AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 16356089 — intervention group
Group type: COMPARATOR
Intervention: TPOAb presence during follow-up
Number of subjects: 2775
Study 11940309 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramipril treatment (n = 21)
Number of subjects: 44
Study 11940309 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 44
Study 9579109 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-h night shifts
Number of subjects: 0
Study 9579109 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-h night shifts
Number of subjects: 0
Study 9579109 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-h day shifts
Number of subjects: 0
Study 9579109 — intervention group
Group type: EXPERIMENTAL
Intervention: Lighter workloads
Number of subjects: 0
Study 9579109 — intervention group
Group type: COMPARATOR
Intervention: Higher workloads
Number of subjects: 0
Study 9579109 — intervention group
Group type: EXPERIMENTAL
Intervention: Work cycle durations
Number of subjects: 0
Study 9579109 — intervention group
Group type: EXPERIMENTAL
Intervention: Night shifts
Number of subjects: 0
Study 8594697 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose diethylcarbamazine (DEC) 6mg/kg
Number of subjects: 0
Study 8594697 — intervention group
Group type: COMPARATOR
Intervention: Standard regimen of 6 doses (total 36 mg/kg) of DEC
Number of subjects: 0
Study 2569857 — intervention group
Group type: EXPERIMENTAL
Intervention: Dilevalol 200 mg qd
Number of subjects: 58
Study 2569857 — intervention group
Group type: COMPARATOR
Intervention: Captopril 100 mg bid
Number of subjects: 58
Study 2569857 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 40 mg bid
Number of subjects: 58
Study 59189 — intervention group
Group type: EXPERIMENTAL
Intervention: Partially purified human interferon (P.I.N.F.)
Number of subjects: 55
Study 59189 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 55
Study 31309910 — intervention group
Group type: EXPERIMENTAL
Intervention: Maltodextrin based milkshake
Number of subjects: 51
Study 31309910 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucose based milkshake
Number of subjects: 51
Study 28431589 — intervention group
Group type: EXPERIMENTAL
Intervention: Albendazole plus antiepileptic drugs
Number of subjects: 123
Study 28431589 — intervention group
Group type: COMPARATOR
Intervention: Antiepileptic treatment (Control)
Number of subjects: 123
Study 26222725 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypothermia (MH) induced by transnasal cooling
Number of subjects: 20
Study 26222725 — intervention group
Group type: COMPARATOR
Intervention: Normothermia (control)
Number of subjects: 20
Study 23402838 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh non-leukoreduced RBC transfusions (stored for less than 1 week)
Number of subjects: 18
Study 23402838 — intervention group
Group type: COMPARATOR
Intervention: Aged non-leukoreduced RBC transfusions (stored for more than 3 weeks)
Number of subjects: 18
Study 23402838 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups received RBC transfusions
Number of subjects: 18
Study 21586692 — intervention group
Group type: EXPERIMENTAL
Intervention: Right Radial Approach (RRA)
Number of subjects: 390
Study 21586692 — intervention group
Group type: COMPARATOR
Intervention: Left Radial Approach (LRA)
Number of subjects: 390
Study 19198223 — intervention group
Group type: EXPERIMENTAL
Intervention: Mecobalamin 1,500 microg/day for 6 months
Number of subjects: 54
Study 19198223 — intervention group
Group type: COMPARATOR
Intervention: Nerve sparing prostatectomy alone
Number of subjects: 54
Study 16995457 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamicine 600mg and gentamicine 80mg, both intramuscularly one hour before the ERCP (group I)
Number of subjects: 61
Study 16995457 — intervention group
Group type: COMPARATOR
Intervention: No antibiotic prophylaxis (group II)
Number of subjects: 61
Study 16995457 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (I and II)
Number of subjects: 61
Study 15298069 — intervention group
Group type: EXPERIMENTAL
Intervention: Olcegepant, a non-peptide CGRP receptor antagonist, details on dosage and duration not available
Number of subjects: 0
Study 11147785 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine supplementation (20 g daily during immobilization, 15 g daily during first 3 weeks of rehabilitation, 5 g daily during last 7 weeks of rehabilitation)
Number of subjects: 22
Study 11147785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (maltodextrin)
Number of subjects: 22
Study 9431261 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylphenidate (MP)
Number of subjects: 0
Study 9431261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8213870 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine treatment
Number of subjects: 17
Study 8213870 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 17
Study 3323166 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 90
Study 3323166 — intervention group
Group type: COMPARATOR
Intervention: Cephradine
Number of subjects: 90
Study 3323166 — intervention group
Group type: COMPARATOR
Intervention: Erythromycin
Number of subjects: 90
Study 3323166 — intervention group
Group type: COMPARATOR
Intervention: Doxycycline
Number of subjects: 90
Study 31473867 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-level laser therapy (LLLT) twice weekly for 6 weeks
Number of subjects: 60
Study 29751819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Health Promotion
Number of subjects: 240
Study 29751819 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Eating Awareness Training
Number of subjects: 240
Study 29751819 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 240
Study 26809770 — intervention group
Group type: EXPERIMENTAL
Intervention: Alternative tumor grade (based on histological and cytological features)
Number of subjects: 381
Study 26809770 — intervention group
Group type: COMPARATOR
Intervention: Traditional tumor grade (based on histological features)
Number of subjects: 381
Study 25048073 — intervention group
Group type: EXPERIMENTAL
Intervention: Countermovement Jump (CMJ)
Number of subjects: 54
Study 25048073 — intervention group
Group type: COMPARATOR
Intervention: Squat Jump (SJ)
Number of subjects: 54
Study 22178819 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention schools (LIFT+ program)
Number of subjects: 1119
Study 22178819 — intervention group
Group type: COMPARATOR
Intervention: Control schools
Number of subjects: 1119
Study 20694481 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil (group R) used in combination with fentanyl as intravenous analgesic.
Number of subjects: 100
Study 20694481 — intervention group
Group type: COMPARATOR
Intervention: Fentanyl alone (group C) as intravenous analgesic.
Number of subjects: 100
Study 18291501 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote control used during ultrasound (group 1)
Number of subjects: 50
Study 18291501 — intervention group
Group type: COMPARATOR
Intervention: No remote control used during ultrasound (group 2)
Number of subjects: 50
Study 18291501 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote control used with vascular duplex sonography (group 1a)
Number of subjects: 50
Study 18291501 — intervention group
Group type: COMPARATOR
Intervention: No remote control used with vascular duplex sonography (group 2a)
Number of subjects: 50
Study 16110933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and irinotecan (CPT-P)
Number of subjects: 103
Study 16110933 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and vindesine
Number of subjects: 103
Study 12579093 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin at 80 mg/m(2) on 1 day and vindesine at 3 mg/m(2) on 2 days) followed by surgery
Number of subjects: 62
Study 12579093 — intervention group
Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 62
Study 12579093 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy
Number of subjects: 62
Study 12579093 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study 10488695 — intervention group
Group type: EXPERIMENTAL
Intervention: HCV RNA seropositive at the beginning of follow-up (310 patients)
Number of subjects: 320
Study 10488695 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with liver cancer (6 patients)
Number of subjects: 320
Study 10488695 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum alanine aminotransferase normalization (11 cases)
Number of subjects: 320
Study 7503064 — intervention group
Group type: EXPERIMENTAL
Intervention: Random urine specimen protein to creatinine (P/C) ratio
Number of subjects: 229
Study 1958276 — intervention group
Group type: EXPERIMENTAL
Intervention: Aza and MP
Number of subjects: 88
Study 1958276 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy (CyA, Aza, MP)
Number of subjects: 88
Study 1958276 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy, Aza + CyA, CyA + MP
Number of subjects: 88
Study 1958276 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple therapy
Number of subjects: 88
Study 1958276 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 88
Study 1958276 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients
Number of subjects: 88
Study 6894708 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained Release (SR) formulation of butriptyline, 75 mg single oral dose
Number of subjects: 14
Study 6894708 — intervention group
Group type: COMPARATOR
Intervention: Conventional formulation of butriptyline, 75 mg single oral dose
Number of subjects: 14
Study 31400634 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 10 mg/kg
Number of subjects: 951
Study 31400634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 951
Study 28230646 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus (EVR) with complete CNI elimination 7 to 11 weeks post-HTx
Number of subjects: 115
Study 28230646 — intervention group
Group type: COMPARATOR
Intervention: Standard CNI immunosuppression
Number of subjects: 115
Study 26852024 — intervention group
Group type: EXPERIMENTAL
Intervention: Cervical and thoracic manipulation
Number of subjects: 110
Study 26852024 — intervention group
Group type: COMPARATOR
Intervention: Mobilization and exercise
Number of subjects: 110
Study 23564504 — intervention group
Group type: EXPERIMENTAL
Intervention: Getting To Outcomes-Underage Drinking (GTO-UD) intervention, including the GTO-UD manual, training, and onsite technical assistance for 16 months.
Number of subjects: 6
Study 23564504 — intervention group
Group type: COMPARATOR
Intervention: Control group maintaining routine operations without GTO-UD intervention.
Number of subjects: 6
Study 23073265 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based educational program (Helping Smokers Quit)
Number of subjects: 333
Study 23073265 — intervention group
Group type: COMPARATOR
Intervention: Printed educational materials (control group)
Number of subjects: 333
Study 23073265 — intervention group
Group type: EXPERIMENTAL
Intervention: Webinar attendance (within intervention group)
Number of subjects: 333
Study 23073265 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall intervention group
Number of subjects: 333
Study 19329279 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel compounds for SLE treatment
Number of subjects: 0
Study 17523483 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon preparations included in complex therapy for ureaplasmosis
Number of subjects: 0
Study 17523483 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation of anaerobic part of vaginal microbiota
Number of subjects: 0
Study 15294260 — intervention group
Group type: EXPERIMENTAL
Intervention: DDD pacing with ATA prevention algorithms
Number of subjects: 55
Study 15294260 — intervention group
Group type: COMPARATOR
Intervention: Conventional DDD pacing
Number of subjects: 55
Study 15294260 — intervention group
Group type: EXPERIMENTAL
Intervention: ATA prevention algorithms in patients with low percentage of ventricular pacing
Number of subjects: 55
Study 15294260 — intervention group
Group type: COMPARATOR
Intervention: Conventional DDD pacing in patients with low percentage of ventricular pacing
Number of subjects: 55
Study 11881128 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 16 mg o.d. for 24 weeks
Number of subjects: 35
Study 9773913 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol (2.5 mg x kg(‐1); 15 mg x kg(‐1) x hr)
Number of subjects: 10
Study 9773913 — intervention group
Group type: COMPARATOR
Intervention: Halothane (1.25%)
Number of subjects: 10
Study 7880557 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone intervention strategy (Tell A Friend program)
Number of subjects: 594
Study 7880557 — intervention group
Group type: COMPARATOR
Intervention: Control group (not contacted by volunteers)
Number of subjects: 594
Study 3204159 — intervention group
Group type: EXPERIMENTAL
Intervention: Enucleation combined with cryotherapy
Number of subjects: 0
Study 3204159 — intervention group
Group type: COMPARATOR
Intervention: Enucleation
Number of subjects: 0
Study 2149513 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (1600 mg max daily dose)
Number of subjects: 35
Study 2149513 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (640 mg max daily dose)
Number of subjects: 35
Study 2149513 — intervention group
Group type: COMPARATOR
Intervention: Control (Placebo for 2 weeks)
Number of subjects: 35
Study 137794 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium valproate
Number of subjects: 1
Study 137794 — intervention group
Group type: COMPARATOR
Intervention: L-Dopa
Number of subjects: 1
Study 31608431 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wireless monitoring of vital signs combined with Efficacy Safety Score (ESS) during the first 24 postoperative hours
Number of subjects: 195
Study 31608431 — intervention group
Group type: COMPARATOR
Intervention: Standard care group (SC-Group)
Number of subjects: 195
Study 31608431 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous wireless monitoring of vital signs combined with Efficacy Safety Score (ESS)
Number of subjects: 195
Study 31124007 — intervention group
Group type: EXPERIMENTAL
Intervention: Breastfeeding self-efficacy
Number of subjects: 547
Study 31124007 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem
Number of subjects: 547
Study 31124007 — intervention group
Group type: EXPERIMENTAL
Intervention: General health
Number of subjects: 547
Study 31124007 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-esteem and general health
Number of subjects: 547
Study 31124007 — intervention group
Group type: EXPERIMENTAL
Intervention: Multivariate linear regression analysis
Number of subjects: 547
Study 31124007 — intervention group
Group type: EXPERIMENTAL
Intervention: Improvement in self-esteem and general health
Number of subjects: 547
Study 28183544 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg rocuronium plus magnesium sulfate 30 mg/kg (group LM)
Number of subjects: 84
Study 28183544 — intervention group
Group type: COMPARATOR
Intervention: 0.6 mg/kg rocuronium (group C)
Number of subjects: 84
Study 28183544 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45 mg/kg rocuronium (group LR)
Number of subjects: 84
Study 25557347 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal breathing for 3 minutes
Number of subjects: 20
Study 25557347 — intervention group
Group type: COMPARATOR
Intervention: Normal breathing for 3 minutes
Number of subjects: 20
Study 23591713 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecalciferol 7,000 IU daily for 26 weeks
Number of subjects: 52
Study 23591713 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 21829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Cold water immersion
Number of subjects: 36
Study 21829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice massage
Number of subjects: 36
Study 21829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Ice pack
Number of subjects: 36
Study 21829988 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking after cooling
Number of subjects: 36
Study 21829988 — intervention group
Group type: COMPARATOR
Intervention: 30 min rest after cooling
Number of subjects: 36
Study 19669785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (Cor, Cortancyl, 50 mg per day for 1 week)
Number of subjects: 9
Study 19669785 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral prednisone (Cor)
Number of subjects: 9
Study 19669785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Pla, gelatin)
Number of subjects: 9
Study 17216323 — intervention group
Group type: EXPERIMENTAL
Intervention: Lateral decubitus position (Group I)
Number of subjects: 41
Study 17216323 — intervention group
Group type: COMPARATOR
Intervention: Supine position (Group II)
Number of subjects: 41
Study 15179648 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive cognitive rehabilitation program (ICRP)
Number of subjects: 56
Study 15179648 — intervention group
Group type: COMPARATOR
Intervention: Standard neurorehabilitation (SRP)
Number of subjects: 56
Study 15179648 — intervention group
Group type: EXPERIMENTAL
Intervention: ICRP
Number of subjects: 56
Study 15179648 — intervention group
Group type: COMPARATOR
Intervention: SRP
Number of subjects: 56
Study 11432122 — intervention group
Group type: EXPERIMENTAL
Intervention: General well-being promotion and adjustment support for patients and caregivers; no specific intervention details provided.
Number of subjects: 0
Study 11432122 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing diagnostic and therapeutic alliance with primary care physicians; no specific intervention details provided.
Number of subjects: 0
Study 9142517 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanate
Number of subjects: 159
Study 9142517 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamicin
Number of subjects: 159
Study 9142517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefazolin
Number of subjects: 159
Study 8198020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/d
Number of subjects: 74
Study 8198020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin 20 mg/d + Niacin (titrated to maximum of 3 g/d)
Number of subjects: 74
Study 8198020 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 74
Study 3556263 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg paracetamol plus 60 mg codeine
Number of subjects: 180
Study 3556263 — intervention group
Group type: COMPARATOR
Intervention: 650 mg paracetamol plus 65 mg dextropropoxyphene
Number of subjects: 180
Study 31604674 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing Benzodiazepine and related drug (BDZR) use
Number of subjects: 448
Study 29214506 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol (1000 mg) co-administered with morphine (0.125 mg/kg)
Number of subjects: 22
Study 29214506 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous paracetamol (1000 mg) co-administered with morphine (0.125 mg/kg)
Number of subjects: 22
Study 29214506 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral paracetamol (1000 mg) after discontinuation of morphine
Number of subjects: 22
Study 28659456 — intervention group
Group type: EXPERIMENTAL
Intervention: Guy2Guy (G2G) HIV prevention program
Number of subjects: 0
Study 28659456 — intervention group
Group type: COMPARATOR
Intervention: Healthy lifestyle control
Number of subjects: 0
Study 25727536 — intervention group
Group type: EXPERIMENTAL
Intervention: Antipsychotics (various types, including olanzapine)
Number of subjects: 404
Study 23326352 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help CBT (GSH-CBT)
Number of subjects: 281
Study 23326352 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 281
Study 21534497 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulation-enhanced orientation
Number of subjects: 76
Study 21534497 — intervention group
Group type: COMPARATOR
Intervention: Control group (traditional orientation)
Number of subjects: 76
Study 19738145 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline carotid intima-media thickness (IMT)
Number of subjects: 2334
Study 19738145 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline number of carotid plaques
Number of subjects: 2334
Study 19738145 — intervention group
Group type: EXPERIMENTAL
Intervention: On-treatment IMT values
Number of subjects: 2334
Study 19738145 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-induced IMT changes
Number of subjects: 2334
Study 16971362 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium hydroxylapatite filler
Number of subjects: 10
Study 14697021 — intervention group
Group type: EXPERIMENTAL
Intervention: Denture users (complete dentures for at least 2 years)
Number of subjects: 302
Study 14697021 — intervention group
Group type: COMPARATOR
Intervention: Non-denture users (never worn removable prostheses)
Number of subjects: 302
Study 10026395 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol without occlusion
Number of subjects: 12
Study 10026395 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcipotriol with occlusion
Number of subjects: 12
Study 10026395 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate without occlusion
Number of subjects: 12
Study 10026395 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate with occlusion
Number of subjects: 12
Study 8561068 — intervention group
Group type: EXPERIMENTAL
Intervention: fiber-rich, high-carbohydrate, low-fat (HCLF) diet
Number of subjects: 16
Study 8561068 — intervention group
Group type: COMPARATOR
Intervention: modified-fat (MF) diet high in monounsaturated fat
Number of subjects: 16
Study 1853306 — intervention group
Group type: EXPERIMENTAL
Intervention: Low molecular weight heparin (LMWH)
Number of subjects: 96
Study 1853306 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH)
Number of subjects: 96
Study 1853306 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative PAI-1 activity
Number of subjects: 96
Study 1853306 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative PAI-1 activity, PAI-1 Ag, and t-PA Ag
Number of subjects: 96
Study 1853306 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative fibrinolytic variables
Number of subjects: 96
Study 6365210 — intervention group
Group type: EXPERIMENTAL
Intervention: Mastectomy
Number of subjects: 38